{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:51:23Z","timestamp":1783032683013,"version":"3.54.6"},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,9,1]]},"DOI":"10.1001\/jamadermatol.2024.2462","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:07:56Z","timestamp":1722438476000},"page":"919","source":"Crossref","is-referenced-by-count":2,"title":["Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis"],"prefix":"10.1001","volume":"160","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[{"name":"Blauvelt Consulting, LLC, Lake Oswego, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan H.","family":"Noe","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ded240008r1","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance.","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"ded240008r2","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"ded240008r3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","article-title":"Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.","volume":"186","author":"Augustin","year":"2022","journal-title":"Br J Dermatol"},{"key":"ded240008r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial.","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"ded240008r5","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"ded240008r6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/24755303221127338","article-title":"Resident memory T cells in psoriasis: key to a cure.","volume":"7","author":"Blauvelt","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"7","key":"ded240008r7","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis.","volume":"192","author":"Cheuk","year":"2014","journal-title":"J Immunol"},{"issue":"77","key":"ded240008r8","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells.","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci Immunol"},{"issue":"7","key":"ded240008r9","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab.","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"8","key":"ded240008r11","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review.","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"ded240008r10","author":"Blauvelt","year":"2024"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2821681\/jamadermatology_blauvelt_2024_ed_240008_1726504996.78422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:03:05Z","timestamp":1726671785000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2821681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.2462","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}